EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway (Q40405623)

20 September 2017

title

EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway (English)

1 reference

20 September 2017

1

1 reference

20 September 2017

Mark I Greene

2

1 reference

20 September 2017

publication date

1 October 2005

1 reference

Experimental and Molecular Pathology

20 September 2017

published in

1 reference

20 September 2017

volume

79

1 reference

20 September 2017

issue

2

1 reference

20 September 2017

page(s)

100-107

1 reference

Chromosomal passengers and the (aurora) ABCs of mitosis

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Regulation of TNFRSF6 (Fas) expression in ataxia telangiectasia cells by ionizing radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Protein kinase B/Akt-mediated phosphorylation promotes nuclear exclusion of the winged helix transcription factor FKHR1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

HER2/Neu: mechanisms of dimerization/oligomerization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Survivin is required for stable checkpoint activation in taxol-treated HeLa cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

ErbB receptors: directing key signaling networks throughout life

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

ErbB2 activation and signal transduction in normal and malignant mammary cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Aberrant regulation of survivin by the RB/E2F family of proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Tumor necrosis factor-alpha and Fas activate complementary Fas-associated death domain-dependent pathways that enhance apoptosis induced by gamma-irradiation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

The role of distinct p185neu extracellular subdomains for dimerization with the epidermal growth factor (EGF) receptor and EGF-mediated signaling.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Control of apoptosis and mitotic spindle checkpoint by survivin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Pleiotropic cell-division defects and apoptosis induced by interference with survivin function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Bim: a novel member of the Bcl-2 family that promotes apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

A p34(cdc2) survival checkpoint in cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Trans receptor inhibition of human glioblastoma cells by erbB family ectodomains.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Conversion of a radioresistant phenotype to a more sensitive one by disabling erbB receptor signaling in human cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Inhibition of a naturally occurring EGFR oncoprotein by the p185neu ectodomain: implications for subdomain contributions to receptor assembly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Cell cycle-dependent regulation of TIAP/m-survivin expression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Induction of the Tat-binding protein 1 gene accompanies the disabling of oncogenic erbB receptor tyrosine kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

p185c-neu and epidermal growth factor receptor associate into a structure composed of activated kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

The ErbB/HER receptor protein-tyrosine kinases and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

MEK/ERK pathway protects ionizing radiation-induced loss of mitochondrial membrane potential and cell death in lymphocytic leukemia cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Human survivin is a kinetochore-associated passenger protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Phosphorylation on tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and is involved in resistance to taxol-induced apoptosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Localization, dynamics, and function of survivin revealed by expression of functional survivinDsRed fusion proteins in the living cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Survivin and the inner centromere protein INCENP show similar cell-cycle localization and gene knockout phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

A point mutation in the neu oncogene mimics ligand induction of receptor aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Structural alterations of the epidermal growth factor receptor gene in human gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Phosphorylation of serine 256 suppresses transactivation by FKHR (FOXO1) by multiple mechanisms. Direct and indirect effects on nuclear/cytoplasmic shuttling and DNA binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.YEXMP.2005.05.002

10.1016/J.YEXMP.2005.05.002

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference